Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV-DNA level < 2000 IU/mL.
Hankil LeeSungin JangSang Hoon AhnBeom Kyung KimPublished in: Hepatology international (2022)
The extended application of AVT in CC-LLV patients may contribute positively to individual clinical benefits and national healthcare budgets.